Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

tislelizumab 4talazoparib 4pembrolizumab 4Docetaxel 4Nivolumab 3PM 01183 2MLN 8237 2Itraconazole 2Fluorouracil 2Cisplatin 2Carboplatin 2zimberelimab 1utomilumab 1urelumab 1ulixertinib 1trifluridine tipiracil drug combination 1sitravatinib 1sapanisertib 1pexidartinib 1pevonedistat 1peposertib 1niraparib 1mogamulizumab 1lenvatinib 1ixabepilone 1eribulin 1durvalumab 1dalotuzumab 1avelumab 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumors × sitravatinib × Clear all
NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
216 enrolled 20 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡